An Overview of Levonadifloxacin in Tertiary Care Hospital: A Systematic Review of Observational Retrospective Study

Abstract

Background: Antibiotic resistance poses a global health challenge, imposing the development of novel antibiotics. Levonadifloxacin, a third-generation fluoroquinolone, exhibits potent antibacterial activity against diverse pathogens, including drug-resistant strains.

Methods: An observational retrospective study was conducted at KIMS multispeciality hospital, Hyderabad, from October 2022 to June 2023. A total of 36 patients aged above 18 years were included, with diagnoses of severe bacterial infections. Data was collected on demographics, treatment details, unwanted effects, and analyse the results using chi-square test.

Results: Levonadifloxacin exhibited a broad spectrum of efficacy against respiratory pathogens. Common unwanted effects included constipation, cough, and decreased haemoglobin levels. Significant associations were found between the prescribed dose of levonadifloxacin and decreased haemoglobin levels (p = 0.02), as well as between treatment duration and increased random blood glucose levels (p = 0.03). Furthermore, levonadifloxacin was correlated with decreased white blood cell levels (p < 0.001).

Conclusion: Levonadifloxacin demonstrated promising efficacy against bacterial infections, with manageable unwanted effects. Significant associations between dose, duration, and specific unwanted effects highlight the need for cautious prescribing and monitoring. These findings underscore the potential of levonadifloxacin as an effective therapeutic option while emphasizing the importance of personalized treatment and careful patient management.